336 results on '"Scherer Florian"'
Search Results
52. Additional file 2 of Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer
53. Early Prediction of Treatment Response By Circulating Tumor DNA Profiling in Patients with Diffuse Large B-Cell Lymphoma Receiving CAR T-Cell Therapy
54. A Randomized, Open-Label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED / GLA 2022-1)
55. Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma
56. Long-Term Follow-up of AML Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation after Primary Induction Failure
57. Phased variants improve DLBCL minimal residual disease detection at the end of therapy.
58. Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis
59. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA
60. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis
61. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
62. Spatiotemporal heterogeneity of glioblastoma is dictated by microenvironmental interference
63. Crosstalk between lymphoid and myeloid cells orchestrates glioblastoma immunity through Interleukin 10 signaling
64. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer
65. Spatially Resolved Multi-Omics Deciphers Bidirectional Tumor-Host Interdependence in Glioblastoma
66. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer
67. Change is Coming: Plan S From the Early Career Scientist Perspective
68. Recurrent Crebbp Mutations in Follicular Lymphoma Appear Localized to the Committed B-Cell Lineage
69. Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
70. Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
71. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA
72. Lineage and Spatial Mapping of Glioblastoma-associated Immunity
73. Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single‐centre analysis
74. The DKTK EXLIQUID consortium – exploiting liquid biopsies to advance cancer precision medicine for molecular tumor board patients
75. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
76. Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA
77. Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
78. Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling
79. Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention
80. Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
81. Reply to J. Wang et al
82. Distinct Chromatin Accessibility Profiles of Lymphoma Subtypes Revealed By Targeted Cell Free DNA Profiling
83. Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
84. Klinische Akzeptanz von oVEMP-Untersuchungen
85. Development of a Dynamic Model for Personalized Risk Assessment in Large B-Cell Lymphoma
86. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling
87. Charge air cooling with an exhaust energy driven cooling device:its influence on exhaust emissions
88. Noninvasive detection of clinically relevant copy number alterations in diffuse large B-cell lymphoma.
89. Elucidation of distinct mutational patterns between diffuse large B cell lymphoma subtypes utilizing circulating tumor DNA.
90. Noninvasive Detection of Ibrutinib Resistance in Non-Hodgkin Lymphoma Using Cell-Free DNA
91. Noninvasive Detection of BCL2, BCL6, and MYC Translocations in Diffuse Large B-Cell Lymphoma
92. Absence of Evidence Implicating Hematopoietic Stem Cells As Common Progenitors for DLBCL Mutations
93. Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma
94. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRASand NRASMutations in Cell-Free DNA
95. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
96. Noninvasive Cancer Classification Using Diverse Genomic Features in Circulating Tumor DNA
97. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
98. Prediction of therapeutic outcomes in DLBCL from circulating tumor DNA dynamics.
99. Inter- and intra-patient heterogeneity of resistance mechanisms to the mutant EGFR selective inhibitor rociletinib.
100. Noninvasive molecular subtyping and risk stratification of DLBCL.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.